Live Chat

Amgen 거래 AMGN

매도
 매수

Amgen 실시간 차트

5m 15m 30m 1h 4h 1d 1w

상품 기초

Weekly Search
Weekly
Daily
날짜 종료 변경 변동(%) 열기 높음 낮음

최신 뉴스

Frances Wang 2024 Dec 02, 16:00

Gold Price Dropped Below $2,650 as US Dollar Rises on Trump Tariff Threat

Commodities
Frances Wang 2024 Dec 02, 16:00

GBP to USD forecast: GBP/USD Records Its Best Week Since September

Forex
Frances Wang 2024 Dec 02, 16:00

Supermicro stock surged almost 30%: Why SMCI Stock Is Surging Again?

Stocks
Frances Wang 2024 Dec 02, 16:00

BTC Price Forecast and Bitcoin Technical Analysis: Will Bitcoin Reach $100K?

Cryptocurrencies
Neil Wilson 2024 Dec 02, 16:00

Week Ahead: Markets on the Move: Stocks Rally Amid Economic Uncertainty

Stocks Morning Note
Frances Wang 2024 Dec 01, 16:00

Forex market news: Japanese Yen Sharply Declines Against USD

Forex
Frances Wang 2024 Dec 01, 16:00

Solana Price Prediction: Will SOL Hit $1,000 after its impressive rebound

Cryptocurrencies
Frances Wang 2024 Dec 01, 16:00

FTSE 100 Index Today: FTSE 100 companies recognize supply chain as key risk

Indices

정보

스프레드

1.89

스프레드(%)

0.6786 %

레버리지

1:10

익일 이자 매수

-0.0597 %

익일 이자 매도

-0.0292 %

통화

USD

거래 시간

시장 개장

화요일

14:31 - 20:59

월요일

14:31-20:59

수요일

14:31-20:59

목요일

14:31-20:59

금요일

14:31-20:59

분석 및 통계

열기

---

이전 종가

---

52주 최고/최저

--- – ---

시가총액

152051957760

발행 주식 수

537532992

수익 날짜 (다음)

1999-11-22

배당수익률

2024-12-09

배당락일

2024-11-18

예상 연간 배당금

9

예상 연간 배당수익률

0.0318

EPS

7.84

이 상품에 대해 자세히 알아보기

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

관련 상품

자산
매도
매수
변동(%)

지금 거래하기

지금 거래하기

지금 거래하기

지금 거래하기
view_all_instruments
Trustpilot
Live Chat